The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 1 study of TPST-1495 as a single agent and in combination with pembrolizumab in patients with advanced solid tumors.
 
Susanna Varkey Ulahannan
Consulting or Advisory Role - AstraZeneca; Eisai; IgM Biosciences
Research Funding - Abbvie (Inst); Adlai Nortye (Inst); ArQule (Inst); Astex Pharmaceuticals (Inst); AstraZeneca (Inst); atreca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); CicloMed (Inst); Erasca, Inc (Inst); evelo biosciences (Inst); Exelixis (Inst); Exelixis (Inst); G1 Therapeutics (Inst); GlaxoSmithKline (Inst); IgM Biosciences (Inst); Incyte (Inst); Klus Pharma (Inst); Macrogenics (Inst); Merck (Inst); Mersana (Inst); NGM Biopharmaceuticals (Inst); OncoMed (Inst); Pfizer (Inst); Pionyr (Inst); Regeneron (Inst); Revolution Medicines (Inst); Synermore biologics (Inst); Takeda (Inst); Takeda (Inst); Tarveda Therapeutics (Inst); Tempest Therapeutics (Inst); Tesaro (Inst); Vigeo Therapeutics (Inst)
 
John D. Powderly
Employment - BioCytics; Carolina BioOncology Institute
Leadership - BioCytics; Carolina BioOncology Institute
Stock and Other Ownership Interests - BioCytics; Carolina BioOncology Institute
Consulting or Advisory Role - Aavocyte; Abbvie; AstraZeneca/MedImmune; Boxer Capital; Genentech/Roche; Phanes Therapeutics; TERUMO; TopAlliance BioSciences Inc
Research Funding - Abbvie; Adagene (Inst); Alkermes; Apros Therapeutics; Arcus Biosciences; Ascendis Pharma (Inst); AstraZeneca/MedImmune; Atreca (Inst); BioBank Online (Inst); BJ Bioscience (Inst); Bristol-Myers Squibb; Calico; CEM Corporation (Inst); Conjupro Biotherapeutics (Inst); Corvus Pharmaceuticals; Cullinan Oncology (Inst); Curis; EMD Serono; Engineered BioPharmaceuticals (Inst); Fate Therapeutics (Inst); FLX Bio; Function Oncology (Inst); Genentech/Roche; I-Mab (Inst); Immune-Onc Therapeutics (Inst); Incyte; Jounce Therapeutics; Lilly/ImClone; Macrogenics; Merck (Inst); Molecular Templates (Inst); MT Group (Inst); NextCure (Inst); Nuvation Bio (Inst); Pioma Chemicals (Inst); Precision for Medicine (Inst); Repertoire Immune Medicines (Inst); Replimune (Inst); Seagen; Sequenom (Inst); STEMCELL Technologies (Inst); Tempest Therapeutics; Therapeutic BrainPower LLC (Inst); Top Alliance BioScience; Trethera (Inst); Xilio Therapeutics (Inst); Xilis (Inst); Zenshine (Inst)
Patents, Royalties, Other Intellectual Property - BioCytics is developing intellectual property for cellular immunotherapy
 
Melissa Lynne Johnson
Consulting or Advisory Role - Abbvie (Inst); Amgen (Inst); ArriVent Biopharma (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Axelia Oncology (Inst); Black Diamond Therapeutics (Inst); Calithera Biosciences (Inst); Checkpoint Therapeutics (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); EcoR1 Capital (Inst); Editas Medicine (Inst); Eisai (Inst); Genentech/Roche (Inst); Genmab (Inst); Genocea Biosciences (Inst); GlaxoSmithKline (Inst); Gritstone Bio (Inst); IDEAYA Biosciences (Inst); ITeos Therapeutics (Inst); Janssen Oncology (Inst); Lilly (Inst); Merck (Inst); Mirati Therapeutics (Inst); Molecular Axiom (Inst); Novartis (Inst); Oncorus (Inst); Pyramid Biosciences (Inst); Regeneron (Inst); Revolution Medicines (Inst); Ribon Therapeutics (Inst); Sanofi (Inst); SeaGen (Inst); Takeda (Inst); Turning Point Therapeutics (Inst); VBL Therapeutics (Inst)
Research Funding - Abbvie (Inst); Acerta Pharma (Inst); Adaptimmune (Inst); Amgen (Inst); Apexigen (Inst); Arcus Biosciences (Inst); Array BioPharma (Inst); Artios (Inst); AstraZeneca (Inst); Atreca (Inst); BeiGene (Inst); BerGenBio (Inst); BioAtla (Inst); Black Diamond Therapeutics (Inst); Boehringer Ingelheim (Inst); Calithera Biosciences (Inst); Carisma Therapeutics (Inst); Corvus Pharmaceuticals (Inst); Curis (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Dracen (Inst); Dynavax Technologies (Inst); Elicio Therapeutics (Inst); EMD Serono (Inst); EQRx (Inst); Erasca, Inc (Inst); Exelixis (Inst); Fate Therapeutics (Inst); Genentech/Roche (Inst); Genmab (Inst); Genocea Biosciences (Inst); GlaxoSmithKline (Inst); Gritstone Bio (Inst); Guardant Health (Inst); Harpoon (Inst); Helsinn Healthcare (Inst); Hengrui Pharmaceutical (Inst); Hutchison MediPharma (Inst); IDEAYA Biosciences (Inst); IGM Biosciences (Inst); Immunitas (Inst); Immunocore (Inst); Incyte (Inst); Janssen (Inst); Kadmon (Inst); Kartos Therapeutics (Inst); Lilly (Inst); Loxo (Inst); Lycera (Inst); Memorial Sloan-Kettering Cancer Center (Inst); Merck (Inst); Merus (Inst); Mirati Therapeutics (Inst); NeoImmuneTech (Inst); Neovia Oncology (Inst); Novartis (Inst); Numab (Inst); Nuvalent, Inc. (Inst); OncoMed (Inst); Palleon Pharmaceuticals (Inst); Pfizer (Inst); PMV Pharma (Inst); Rain Therapeutics (Inst); Regeneron (Inst); Relay Therapeutics (Inst); Revolution Medicines (Inst); Ribon Therapeutics (Inst); Rubius Therapeutics (Inst); Sanofi (Inst); Seven and Eight Biopharmaceuticals (Inst); Shattuck Labs (Inst); Silicon Therapeutics (Inst); Stem CentRx (Inst); Syndax (Inst); Takeda (Inst); Tarveda Therapeutics (Inst); TCR2 Therapeutics (Inst); Tempest Therapeutics (Inst); Tizona Therapeutics, Inc. (Inst); Tmunity Therapeutics, Inc. (Inst); Turning Point Therapeutics (Inst); University of Michigan (Inst); Vyriad (Inst); Y-mAbs Therapeutics (Inst)
Travel, Accommodations, Expenses - Abbvie; AstraZeneca; Genentech; Incyte; Merck; Pfizer; Sanofi
 
John C. Krauss
Research Funding - Abbvie (Inst); Abbvie (Inst); ACCRU (Inst); Alliance for Clinical Trials in Oncology (Inst); Alliance for Clinical Trials in Oncology (Inst); Alliance for Clinical Trials in Oncology (Inst); Amgen (Inst); AstraZeneca/MedImmune (Inst); Boehringer Ingelheim (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb/Medarex (Inst); Cardiff Oncology; Daiichi Sankyo/Arqule (Inst); Hutchison MediPharma (Inst); Ignyta (Inst); Isofol Medical (Inst); Novartis (Inst); NSABP Foundation (Inst); NSABP FOUNDATION (Inst); Pfizer (Inst); Tempest Therapeutics (Inst); Tempest Therapeutics (Inst)
 
Manish Sharma
Stock and Other Ownership Interests - Abbott Laboratories; Abbvie; Amgen; Biogen; Bristol-Myers Squibb; Gilead Sciences; Johnson & Johnson/Janssen; Lilly; Merck; Moderna Therapeutics; Pfizer; Regeneron; Vertex; West Pharmaceutical
Consulting or Advisory Role - Pliant
Research Funding - Abbvie (Inst); Agenus (Inst); Alexo Therapeutics (Inst); Alkermes (Inst); Alpine Immune Sciences (Inst); Arrys Therapeutics (Inst); Ascentage Pharma (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bolt Biotherapeutics (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Compugen (Inst); Constellation Pharmaceuticals (Inst); Cullinan Oncology (Inst); CytomX Therapeutics (Inst); Debiopharm Group (Inst); eFFECTOR Therapeutics (Inst); Epizyme (Inst); Exelixis (Inst); Genmab (Inst); Gilead Sciences (Inst); GlaxoSmithKline/Tesaro (Inst); Helsinn Therapeutics (Inst); Ikena Oncology (Inst); InhibRx (Inst); Johnson & Johnson/Janssen (Inst); Jounce Therapeutics (Inst); Kinnate Biopharma (Inst); KLUS Pharma (Inst); KSQ Therapeutics (Inst); Loxo (Inst); Macrogenics (Inst); Merck (Inst); Mersana (Inst); NGM Biopharmaceuticals (Inst); Odonate Therapeutics (Inst); Onconova Therapeutics (Inst); Palleon Pharmaceuticals (Inst); Pfizer (Inst); PureTech (Inst); Regeneron (Inst); Repare Therapeutics (Inst); Samumed (Inst); Sapience Therapeutics (Inst); Seagen (Inst); Seven and Eight Biopharmaceuticals (Inst); Shattuck Labs (Inst); SK Life Sciences (Inst); Symphogen (Inst); Syros Pharmaceuticals (Inst); Tempest Therapeutics (Inst); Theratechnologies (Inst); Tizona Therapeutics, Inc. (Inst); Treadwell Therapeutics (Inst)
 
Diwakar Davar
Honoraria - ACM Biolabs; Clinical Care Options (CCO); Gerson Lehrman Group; Medical Learning Group; Merck; Xilio Therapeutics
Consulting or Advisory Role - Checkmate Pharmaceuticals; Clinical Care Options; Finch Therapeutics; Gerson Lehrman Group; Xilio Therapeutics
Speakers' Bureau - Castle Biosciences
Research Funding - Arcus Biosciences; CellSight Technologies; Checkmate Pharmaceuticals; GlaxoSmithKline; Merck; Merck; Zucero Therapeutics (Inst)
Patents, Royalties, Other Intellectual Property - Application No.: 63/124,231; Enteric Microbiotype Signatures of Immune-related Adverse Events and Response in Relation to Anti-PD-1 Immunotherapy
 
Thomas Benjamin Karasic
Honoraria - AstraZeneca/MedImmune; Incyte; Ipsen; Pfizer; Taiho Oncology
Consulting or Advisory Role - Incyte; Nucorion Pharmaceuticals
Research Funding - Bristol-Myers Squibb (Inst); Genentech (Inst); H3 Biomedicine (Inst); Incyte (Inst); Lilly (Inst); Taiho Pharmaceutical (Inst); Tempest Therapeutics (Inst); Xencor (Inst)
 
Stephanie Gaillard
Consulting or Advisory Role - Arcus Biosciences; AstraZeneca; Curio Science; Elevar Therapeutics; Elevar Therapeutics; GlaxoSmithKline; Immunogen; Novartis
Research Funding - AstraZeneca (Inst); Compugen (Inst); Genentech/Roche (Inst); Iovance Biotherapeutics (Inst); Pfizer (Inst); PharmaMar (Inst); Tesaro (Inst)
Patents, Royalties, Other Intellectual Property - Sermonix Pharmaceuticals
 
Yonchu Jenkins
Employment - Abalone Biosciences (I); Calithera Biosciences; Second Genome (I); Tempest Therapeutics
Stock and Other Ownership Interests - Bristol-Myers Squibb (I); Johnson & Johnson/Janssen (I); Novartis (I); Seagen (I); Vertex (I)
Consulting or Advisory Role - Calithera Biosciences; Xoma (I)
 
Robert J. Stagg
Stock and Other Ownership Interests - Abbvie; BeiGene; BridgeBio Pharma; Johnson & Johnson/Janssen; Johnson & Johnson/Janssen; Lilly; Mereo BioPharma; Nkarta; Pfizer; Tempest Therapeutics
Consulting or Advisory Role - Mereo BioPharma; OncXerna Therapeutics; Tempest Therapeutics
Patents, Royalties, Other Intellectual Property - METHODS AND COMPOSITIONS FOR TREATMENT OF CANCER Publication number: 20190023776 Abstract: The present invention relates to VEGF-binding agents, DLL4-binding agents, VEGF/DLL4 bispecific binding agents, and methods of using the agents for treating diseas; Methods and Monitoring of Treatment with a DLL4 Antagonist Publication number: 20140227252 Abstract: Methods for treating diseases such as cancer comprising administering a DLL4 antagonist, either alone or in combination with other anti-cancer agents, an; Methods and Monitoring of Treatment With A DLL4 Antagonist Publication number: 20170299598 Abstract: Methods for treating diseases such as cancer comprising administering a DLL4 antagonist, either alone or in combination with other anti-cancer agents, an; Methods and monitoring of treatment with a WNT pathway inhibitor Patent number: 9987357 Abstract: Methods for treating diseases such as cancer comprising administering a Wnt pathway inhibitor, either alone or in combination with other anti-cancer agents,; METHODS FOR TREATING CANCER WITH DLL4 ANTAGONISTS Publication number: 20130323265 Abstract: The present invention provides methods for treating cancer. More particularly, the invention provides methods for treating cancer comprising administrating doses; Methods for Treating Cancer with DLL4 Antagonists Publication number: 20160324961 Abstract: The present invention provides methods for treating cancer. More particularly, the invention provides methods for treating cancer comprising administrating doses; METHODS OF TREATING NEUROENDOCRINE TUMORS USING FRIZZLED-BINDING AGENTS Publication number: 20160235844 Abstract: Novel methods of treating neuroendocrine tumors are provided. In one embodiment, the method comprises administering to a subject in need the; Methods of treatment with DLL4 antagonists and an anti-hypertensive agent Patent number: 8883145 Abstract: Methods for treating cancer comprising administering a DLL4 antagonist and one or more anti-hypertensive agents are described. Also described are p; Therapeutic combination and methods of treatment with a DLL4 antagonist and an anti-hypertensive agent Patent number: 10870693 Abstract: Methods for treating cancer comprising administering a DLL4 antagonist and one or more anti-hypertensive agents are d
 
Darrin Bomba
Employment - CytomX Therapeutics; Kezar Life Sciences; Tempest Therapeutics
Stock and Other Ownership Interests - Kezar Life Sciences; Tempest Therapeutics
 
Nathan Standifer
Employment - Tempest Therapeutics
Stock and Other Ownership Interests - Tempest Therapeutics
Patents, Royalties, Other Intellectual Property - Tempest Therapeutics
Travel, Accommodations, Expenses - Tempest Therapeutics
Other Relationship - AstraZeneca
 
Steven Smith
Consulting or Advisory Role - AtlasMedx; Mineralys Therapeutics; Syndax; Tempest Therapeutics
 
Peppi Prasit
Employment - Genesis Therapeutics
Leadership - Genesis Therapeutics
Stock and Other Ownership Interests - Genesis Therapeutics
Consulting or Advisory Role - Structure Therapeutics; Tempest Therapeutics
Patents, Royalties, Other Intellectual Property - Inception Sciences
 
Thomas Walter Dubensky
Employment - Tempest Therapeutics
Leadership - Tempest Therapeutics
Stock and Other Ownership Interests - Tempest Therapeutics; Tempest Therapeutics; Tempest Therapeutics; Tempest Therapeutics
Consulting or Advisory Role - Avidea Technologies; Oncorus
Patents, Royalties, Other Intellectual Property - Multiple issued (ca. 40) and pending patents, all of which have been assigned to the various companies which own the rights to them (e.g., Novartis, Chinook, Tempest). I receive no royalties from any of these patents.
 
Sam H. Whiting
Employment - Calithera Biosciences; Recludix Pharma (I); Seagen (I); Tempest Therapeutics
Leadership - Recludix Pharma (I); Tempest Therapeutics
Stock and Other Ownership Interests - Recludix Pharma (I); Tempest Therapeutics
 
Kyriakos P. Papadopoulos
Consulting or Advisory Role - Basilea; Bicycle Therapeutics; Turning Point Therapeutics
Research Funding - 3D Medicines (Inst); Abbvie (Inst); ADC Therapeutics (Inst); Amgen (Inst); Anheart Therapeutics (Inst); Bayer (Inst); Bicycle Therapeutics (Inst); Biontech (Inst); Calithera Biosciences (Inst); Daiichi Sankyo (Inst); EMD Serono (Inst); F-star (Inst); Incyte (Inst); Jounce Therapeutics (Inst); Kezar Life Sciences (Inst); Lilly (Inst); Linnaeus Therapeutics (Inst); MabSpace Biosciences (Inst); MedImmune (Inst); Merck (Inst); Mersana (Inst); Mirati Therapeutics (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Regeneron (Inst); Syros Pharmaceuticals (Inst); Tempest Therapeutics (Inst); Treadwell Therapeutics (Inst)